drugset / Trial / NCT04447846
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
Phase 2
Completed
11 enrolled
Anne Comi, MD
Faneca 66 Foundation · collabJazz Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to better understand the utility of cannabidiol (CBD/ Epidiolex) for improving the treatment of cognitive impairments in Sturge-Weber syndrome (SWS).
Timeline
- Start
- 2019-10-14
- Primary completion
- 2021-08-16
- Completion
- 2022-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 20 mg/kg | Oral |